Gliclazide NEW

Gliclazide is a 2nd generation oral sulfonylurea hypoglycemic agent with strong action. Its mechanism is similar to that of toluenosulfonylurea, i.e., it selectively acts on pancreatic β-cells to promote insulin secretion and enhance insulin release after eating glucose, which can not only improve the metabolism of diabetic patients, but also improve or delay the occurrence of diabetic vascular complications.
Gliclazide is mainly used for mild and moderate type II diabetes mellitus with adult-onset where diet and exercise control alone are ineffective and without a tendency to ketosis, and also improves fundus lesions and metabolic and vascular dysfunctions in diabetic patients.